Site-Specific Drug Delivery

Dr. Wolfram and her research team in the Nanomedicine and Extracellular Vesicles Laboratory are helping address the urgent need to develop strategies for site-specific delivery of drugs to increase therapeutic efficacy and reduce side effects from standard cancer treatments.

In the case of conventional drugs, only 0.001 to 0.01 percent of the systemically injected dose will reach the target tissue.

Nanoparticles are designed to utilize disease-specific and organ-specific characteristics to substantially improve the biodistribution of drugs. Several nanoparticles have received clinical approval by regulatory agencies in various countries, including the Food and Drug Administration in the United States, and many more are in clinical trials.

Dr. Wolfram's Nanomedicine and Extracellular Vesicles Lab is developing strategies to improve drug delivery by using synthetic and biological nanoparticles.

A major focus of research in Dr. Wolfram's lab is the use of extracellular vesicles as drug carriers.

Extracellular vesicles have complex biological membranes that display intrinsic targeting capabilities that can be used for drug delivery.

Another focus of the Nanomedicine and Extracellular Vesicles Lab is modulation of the innate immune system for improved nanoparticle biodistribution.